Wnt/β-catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant activation of this pathway is associated with cell proliferation, invasive behaviors, and cell resistance, suggesting its potential value as a therapeutic target in treatment of CRC. Several agents have been developed for targeting of this pathway (e.g, natural agents: curcumin, 3,3-diindolylmethane, phytoestrogen; Synthetic/small Wnt inhibitors: Rofecoxib; PRI-724, CWP232291; and monoclonal antibody against frizzled receptors, Vanituctumab). This review summarizes the current knowledge about the therapeutic potential of targeting Wnt pathway with particular emphasis on preclinical/clinical studies in treatment of colorectal cancer. J. Cell. Biochem. 118: 1979-1983, 2017. © 2017 Wiley Periodicals, Inc.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcb.25903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating convalescent plasma therapy in severe COVID-19: a retrospective cohort study.
J Infect Dev Ctries
December 2024
Department of Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Introduction: Convalescent plasma (CP) therapy is a form of passive immunization which has been used as a treatment for coronavirus disease 2019 (COVID-19). This study aims to evaluate the efficacy and safety of CP therapy in patients with severe COVID-19.
Methodology: In this retrospective cohort study, 50 patients with severe COVID-19 treated with CP at Shahid Beheshti Hospital, Kashan, in 2019 were evaluated.
Insights of community pharmacists on antibiotic misuse during the COVID-19 pandemic in the northern region of Cyprus.
J Infect Dev Ctries
December 2024
Faculty of Medicine, Eastern Mediterranean University, Famagusta, N. Cyprus via Mersin 10, Turkey.
Introduction: The global healthcare system faced unparalleled challenges during the coronavirus disease 2019 (COVID-19) pandemic, potentially reshaping antibiotic usage trends. This study aimed to evaluate the knowledge, perceptions, and observations of community pharmacists concerning antibiotic utilization during and after the pandemic; and offer crucial insights into its impact on antibiotic usage patterns and infection dynamics.
Methodology: This cross-sectional study involved 162 community pharmacists in Northern Cyprus.
Effect of hemoperfusion in critically ill COVID-19 patients: a case series from a single-center hospital in Indonesia.
J Infect Dev Ctries
December 2024
Intensive Care Unit, Columbia Asia Hospital, Semarang, Indonesia.
Introduction: Hemoperfusion (HP), a blood filtration method targeting the removal of toxins and inflammatory elements, was investigated in this study. The objective was to present the observations in four individuals with confirmed COVID-19 who underwent several rounds of HP utilizing the HA330 cartridge at a hospital in Indonesia.
Case Studies: We report four cases of COVID-19 patients who underwent HP.
Nevoid basal cell carcinoma syndrome (Gorlin syndrome): a case report.
J Med Case Rep
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Background: Basal cell nevus syndrome, also known as Gorlin or Gorlin-Goltz syndrome, is a hereditary condition caused by mutation in the PATCHED gene. The syndrome presents with a wide range of clinical manifestations, including basal cell carcinomas, jaw cysts, and skeletal anomalies. Diagnosis is based on specific criteria, and treatment typically includes surgical removal of basal cell carcinomas.
View Article and Find Full Text PDFMetabolic adaptations to acute glucose uptake inhibition converge upon mitochondrial respiration for leukemia cell survival.
Cell Commun Signal
January 2025
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
One hallmark of cancer is the upregulation and dependency on glucose metabolism to fuel macromolecule biosynthesis and rapid proliferation. Despite significant pre-clinical effort to exploit this pathway, additional mechanistic insights are necessary to prioritize the diversity of metabolic adaptations upon acute loss of glucose metabolism. Here, we investigated a potent small molecule inhibitor to Class I glucose transporters, KL-11743, using glycolytic leukemia cell lines and patient-based model systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!